The focus is not on clinical diagnostics, but on scientific analysis. Research institutions can use the assays to analyse virus sequences, evaluate environmental samples or monitor wastewater for signs of possible spread. Wastewater monitoring in particular has established itself as an important early warning system for infection events in recent years. At the same time, this development shows the extent to which preparation for future health crises is changing. Today, modern molecular platforms must be flexible enough to be adapted to new pathogens within a very short time. As soon as reliable genome data is available, research institutions worldwide should be able to react immediately. For QIAGEN, the provision of the new assays is part of a broader strategy. The company combines sample preparation, sequencing, digital PCR and bioinformatics into integrated research workflows that support laboratories in analysing emerging infectious diseases. The current Ebola outbreak makes it clear that global healthcare no longer starts in hospitals. It starts in research laboratories, databases and surveillance systems that recognise new threats before they can spread uncontrollably.
Press release from "QIAGEN" dated 28 May 2026